Sanofi India Limited has scheduled an analyst and institutional investor meeting for April 1, 2026, in Mumbai, starting at 9:00 AM IST. According to the company's disclosure on March 24, 2026, the in-person meetings are being organized under SEBI Regulation 30 compliance, with discussions strictly limited to publicly available information and no unpublished price sensitive information to be disclosed. The company has emphasized that the meeting schedule remains flexible and subject to change based on exigencies from either investors or the company.
The pharmaceutical company has issued a mandatory notice for transfer of unclaimed equity shares to the Investor Education and Protection Fund (IEPF) Authority for shareholders who have not claimed dividends for seven consecutive years or more. As per the company's notice dated March 13, 2026, affected shareholders have until June 13, 2026 to claim their dividends and shares before automatic transfer to IEPF. The company has published newspaper advertisements on March 14, 2026, in Business Standard (English) and Sakal (Marathi) newspapers, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Board of Directors of Sanofi India has recommended a final dividend of ₹48 per equity share for the financial year ended December 31, 2025. According to the exchange filing reported by ET Now, the board meeting was held on February 25, 2026, with the dividend subject to approval at the ensuing 70th Annual General Meeting. The company announced this development as shares of Sanofi India are expected to remain in focus following the dividend approval.
Sanofi India has announced the record date for its final dividend as April 22, 2026. As reported by ET Now, the register of members and share transfer books will remain closed from April 23-29, 2026, inclusive. The company stated that payment will be made to shareholders whose names appear on the register as of April 22, 2026, or as beneficial owners as per depositories NSDL and CDSL records.
The dividend approval is expected to keep Sanofi India shares in focus in the coming days, according to ET Now reports. The pharmaceutical company's decision to approve this final dividend for FY25 represents a significant payout to shareholders, with the record date set well in advance to allow proper processing and settlement of the dividend payments. For shareholders affected by the IEPF transfer notice, recovery is possible through the IEPF-5 e-form process by obtaining an entitlement letter and submitting required documents as enumerated on the IEPF website at www.iepf.gov.in.
